CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 41 enrolled
Drug / intervention
Ivermectindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05085665
NCT05085665Phase 4Completed
CompareCT.gov

Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events

Washington University School of Medicine·interventional·Posted Oct 20, 2021·Updated Sep 29, 2022

In Brief

A Phase 4 clinical trial evaluating Ivermectin for Loiasis. Completed, enrolled 41 participants across 1 site.

Detailed Summary

This study seeks to determine which Loa loa antigens are released into circulation when infected individuals are treated with ivermectin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLoiasis
CountriesCameroon
CollaboratorsCenter for Research on Filariasis and Other Tropical Diseases, Cameroon

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedOct 20, 2021
Enrollment StartJul 30, 2021
Primary CompletionAug 31, 2021
Study CompletionSep 30, 2021
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 4.7 years ago

Interventions

Ivermectindrug

single dose, 150 ug/kg